ImmuPharma PLC provided further details of patient participation following confirmation in December that ImmuPharma had successfully completed, on target, patient recruitment into its pivotal Phase III clinical trial of Lupuzor. Study Summary: 200 patients successfully recruited and randomised (dosed)- 293 patients initially screened illustrating the demand from physicians for a new safe and effective treatment for Lupus; 7 Countries and 28 sites are participating in the study- US: 11 sites with 70 patients randomized, Europe: 5 Countries and 16 sites with 81 patients randomized, Mauritius:  1 site with 49 patients randomized. Study status as at the end of January 2017: over 80% of patients will have been treated for at least 3 months, 2 patients have completed the study, 24 patients will have been treated for 9 months, 50 patients will have been treated for 6 months, and 90 patients will have been treated for 3 months. To date no drug (active or placebo) related 'Serious Adverse Events' have been reported.  This is consistent with the strong safety profile of Lupuzor shown in its Phase IIb study. Top line results estimated to be reported in first quarter of 2018.